Business
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023
CAMBRIDGE, Mass., March 14, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely
About this update from Nuvalent, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., March 14, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming preclinical data poster presentation supporting the ongoing clinical development of its ALK-selective inhibitor, NVL-655. The data, resulting from a collaboration with the Yonsei University College of Medicine, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.\n\n \n \n \n \n \n \n\n \nThe poster describes the preclinical intracranial antitumor activity of NVL-655 in a brain-implanted xenograft model derived from a patient with lung cancer harboring the alectinib-resistant EML4-ALK v3 G1202R mutation. The poster additionally expands the characterization of NVL-655 alongside other ALK inhibitors. NVL-655 has previously demonstrated intracranial efficacy in a cell line-derived xenograft model as well as broad preclinical activity across diverse ALK resistance mutations and tumor types while maintaining high selectivity for ALK over TRKB. NVL-655 is currently being investigated in the ALKOVE-1 study (NCT05384626), a first-in-human Phase 1/2 clinical trial for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors.\nThe poster will be archived on the Nuvalent website at www.nuvalent.com following the presentation.\nDetails for the poster presentation are as follows:\nTitle: Preclinical intracranial activity of NVL-655 in an alectinib-resistant patient-derived model harboring EML4-ALK fusion with G1202R mutationAuthors: Jii Bum Lee*1, Mi Ra Yu*1, Mi Ran Yun1, You Won Lee1, Seung Yeon Oh1, Eun Ji Lee1, Anupong Tangpeerachaikul2, Henry E. Pelish2, Byoung Chul Cho1 Presenter: Anupong Tangpeerachaikul, Ph.D.Permanent Abstract: 4022Session Category: Experimental and Molecular TherapeuticsSession Title: Tyrosine Kinase and Phosphatase Inhibitors 1Session Date and Time: Tuesday April 18, 2023 from 9:00 a.m. – 12:30 p.m. ETLocation: Orange County Convention Center, Poster Section 201Yonsei University College of Medicine, Seoul, Republic of Korea 2Nuvalent Inc., Cambridge, MA, USA *Equal contributions\nAbout NVL-655\nNVL-655 is a novel brain-penetrant ALK-selective inhibit...